These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 8544852)

  • 21. Selective induction of protection against influenza virus infection in mice by a lipid-peptide conjugate delivered in liposomes.
    Friede M; Muller S; Briand JP; Plaué S; Fernandes I; Frisch B; Schuber F; Van Regenmortel MH
    Vaccine; 1994 Jul; 12(9):791-7. PubMed ID: 7975857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A strategy for making synthetic peptide vaccines.
    Ogasawara K; Naruse H; Itoh Y; Gotohda T; Arikawa J; Kida H; Good RA; Onoé K
    Proc Natl Acad Sci U S A; 1992 Oct; 89(19):8995-9. PubMed ID: 1409595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge.
    Fries LF; Dillon SB; Hildreth JE; Karron RA; Funkhouser AW; Friedman CJ; Jones CS; Culleton VG; Clements ML
    J Infect Dis; 1993 Mar; 167(3):593-601. PubMed ID: 8440931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity.
    Ross KA; Loyd H; Wu W; Huntimer L; Ahmed S; Sambol A; Broderick S; Flickinger Z; Rajan K; Bronich T; Mallapragada S; Wannemuehler MJ; Carpenter S; Narasimhan B
    Int J Nanomedicine; 2015; 10():229-43. PubMed ID: 25565816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli.
    Zeng W; Azzopardi K; Hocking D; Wong CY; Robevska G; Tauschek M; Robins-Browne RM; Jackson DC
    Vaccine; 2012 Jul; 30(32):4800-6. PubMed ID: 22634295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
    Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
    J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus.
    Jeon SH; Ben-Yedidia T; Arnon R
    Vaccine; 2002 Jun; 20(21-22):2772-80. PubMed ID: 12034104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine.
    Pöltl-Frank F; Zurbriggen R; Helg A; Stuart F; Robinson J; Glück R; Pluschke G
    Clin Exp Immunol; 1999 Sep; 117(3):496-503. PubMed ID: 10469053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formulation development of a plant-derived H1N1 influenza vaccine containing purified recombinant hemagglutinin antigen.
    Iyer V; Liyanage MR; Shoji Y; Chichester JA; Jones RM; Yusibov V; Joshi SB; Middaugh CR
    Hum Vaccin Immunother; 2012 Apr; 8(4):453-64. PubMed ID: 22370514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.
    Bianchi E; Liang X; Ingallinella P; Finotto M; Chastain MA; Fan J; Fu TM; Song HC; Horton MS; Freed DC; Manger W; Wen E; Shi L; Ionescu R; Price C; Wenger M; Emini EA; Cortese R; Ciliberto G; Shiver JW; Pessi A
    J Virol; 2005 Jun; 79(12):7380-8. PubMed ID: 15919893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.
    Yong CY; Yeap SK; Ho KL; Omar AR; Tan WS
    Int J Nanomedicine; 2015; 10():2751-63. PubMed ID: 25897220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assembly of synthetic peptide vaccines by chemoselective ligation of epitopes: influence of different chemical linkages and epitope orientations on biological activity.
    Zeng W; Ghosh S; Macris M; Pagnon J; Jackson DC
    Vaccine; 2001 Jul; 19(28-29):3843-52. PubMed ID: 11427256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Free radical induced polymerization of synthetic peptides into polymeric immunogens.
    Jackson DC; O'Brien-Simpson N; Ede NJ; Brown LE
    Vaccine; 1997 Oct; 15(15):1697-705. PubMed ID: 9364702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Presentation by a major histocompatibility complex class I molecule of nucleoprotein peptide expressed in two different genes of an influenza virus transfectant.
    Isobe H; Moran T; Li S; Young A; Nathenson S; Palese P; Bona C
    J Exp Med; 1995 Jan; 181(1):203-13. PubMed ID: 7528768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines.
    Johansson BE; Brett IC
    Hum Vaccin; 2008; 4(6):420-4. PubMed ID: 18535408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region.
    Sagawa H; Ohshima A; Kato I; Okuno Y; Isegawa Y
    J Gen Virol; 1996 Jul; 77 ( Pt 7)():1483-7. PubMed ID: 8757990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.